Abstract
Hepatitis B virus and hepatitis C virus remains one of the leading causes of morbidity and mortality worldwide, particularly in countries with limited resources. The two hepatotropic viruses have common mode of transmission. Hepatitis B virus and hepatitis C virus are the main causes of Cirrhosis, liver cancer and death. To determine the Seroprevalence of HBsAg and anti-HCV antibodies among clinically suspected cases of viral hepatitis visiting Guhalla Primary Hospital, Northwest Ethiopia. A hospital-based retrospective study was conducted at Guhalla Primary Hospital, Northwest Ethiopia. The study included serology registration logbook data from all patients who visited the hospital and were tested using a rapid test kit between September 1st, 2017 to August 30, 2021. Data were entered, cleaned, and analyzed using SPSS version 26 software. Bivariate analysis was computed and a multivariable analysis was conducted to provide an adjusted odds ratio (AOR). p-value < 0.05 at a 95% confidence interval was considered statistically significant. In this study, a total of 883(883 for HBV and 366 for HCV) study participants were included. The overall prevalence of HBsAg and anti-HCV were 124/883(14%) and 73/366 (19.9%), respectively. The prevalence of HBV and HCV among males from the total HBV and HCV screened was 70/410 (17.1%) and 53/366(14.4%) respectively. In this study, being female (AOR 1.53, 95% CI 1.03–2.27, p = 0.003) and age group of 31–40 years (AOR 2.85; 95% CI 1.56, 5.17, p = 0.001) were statistically significant factors to HBV infection. Similarly, being female (AOR 1.97, 95% CI 1.10–3.53, p = 0.02), age group of 21–30 years (AOR 2.71; 95% CI 1.15, 6.40, p = 0.02) and age group greater than 40 years (AOR 3.13; 95% CI 1.31, 7.44, p = 0.01) were significantly associated with HCV infection. In our study, high seroprevalence of HBV and HCV infection was detected among clinically suspected patients. Females and the age groups between 31 and 40 were more affected. Community awareness of the prevention and transmission of viral hepatitis infection should be strengthened through herd immunization and health education. The prospective study should be conducted in this area.
Similar content being viewed by others
Introduction
Hepatitis is an inflammatory liver disease that is mostly caused by viral infection. Hepatitis B and C virus (HBV and HCV) infections are responsible for a significant percentage of liver diseases globally1. Hepatitis B virus (HBV) is a DNA virus that is part of the Hepadnaviridae family, which is made up of a distinct kind of DNA genomic virus. HCV is an RNA virus that is a member of the Flaviviridae family of viruses. The infection with HBV may spontaneously resolve and lead to protective immunity, chronic infection, and, in rare cases, acute liver failure with a high risk of death. An infection with HCV becomes chronic in most cases. People who have a long-term infection with HBV, HCV, or both are still contagious with the risk of developing life-threatening liver conditions including cirrhosis or heptocellular carcinoma (HCC)2,3.
Around one-third of the world's population has been exposed to HBV and an estimated 350–400 million people are chronically infected2,4. Approximately 350 million individuals have been infected with HBV and each year, an estimated 1 million persons die from chronic complications of the disease. Although chronic HBV infection has a worldwide distribution, the vast majority of infected persons reside in Asia, the Middle East, and Africa Globally, cirrhosis, liver cancer, and chronic HBV infection are thought to be the causes of 1.2 million annual deaths5. In Ethiopia, a nation in Africa, hepatitis B surface antigen (HBsAg) prevalence ranges from 6 to 12% in both adults and children. Furthermore, 31% of deaths on medical wards and 12% of hospital admissions are related to liver cirrhosis, hepatocellular carcinoma, acute and chronic viral hepatitis6,7.According to estimates from the World Health Organisation (WHO), 120–170 million persons worldwide are expected to be infected with HCV, representing 3% of the global population8,9.
There is a noticeable regional variance in the frequency and incidence of both HBV and HCV; it may be due to inadequate health facilities, low socioeconomic status, and a lack of public awareness regarding the spread of serious infectious diseases10. Patients with acute or persistent infection have a well-documented phenomenon where HCV suppresses HBV replication. The titer of serum HBsAg was significantly reduced in chimpanzees used in an in vivo study demonstrating acute HCV superinfection in chronic HBV infection11,12. The routes of transmission of HBV and HCV are similar, and co-infection with both viruses is frequent, particularly in regions where HBV infection is endemic and in individuals who are at a high risk of contracting parenteral infection13.
The hepatitis B and hepatitis C viruses have a common mode of transmission that can be spread by the transfusion of contaminated blood, the use of contaminated devices during medical operations, and other risky behaviors. High-efficiency transmission routes for HBV also include perinatal and sexual exposure14. Patients with dual HBV and HCV infection have more severe liver disease and are at increased risk of progression to HCC13. Most persons infected with HBV as adults will recover fully, however, most people infected with HBV as children will develop chronic infection2.
In general, a substantial rate of infection has been repeatedly demonstrated in patients with clinical suspicion of HBV and HCV. Little is known about the prevalence of hepatitis infection in developing countries like Ethiopia. There is a lack of awareness among carers regarding the severity of this disease. Thus this study was conducted to determine the Seroprevalence of HBsAg and anti-HCV antibodies among clinically suspected cases of viral hepatitis visiting Guhalla Primary Hospital, Northwest Ethiopia.
Materials and methods
Study design, area, and period
A hospital-based retrospective study was conducted at Guhala Primary Hospital, North-West Ethiopia, from September 1st, 2017 to August 30, 2021. Guhala is the capital town of East Belesa, located northwest of Addis Ababa (the capital city of Ethiopia), which is 718 km away. Guhala town has an estimated total population of 148,758, of whom 75,732 were males and 73,026 were females. The town has only one public primary hospital, one health center, one health post, and four private health facilities. Guhala Primary Hospital is the only public hospital in east Belesa woreda. Today, the hospital is providing health services to a total population of about 148,758. The data collection period was from July to September 2022.
Study population, sample size, and sampling technique
The source populations were all patients who visited Guhala Primary Hospital and their HBV and HCV test results were registered in the serology Laboratory Logbook. The study population was all patients who had been suspected of having HBV and HCV infection and whose HBV and HCV results were registered in the serology Laboratory registration logbook for the last four years. Data showed HBV and HCV statuses, years, ages, and sex were included in this study. Patient information with incomplete socio-demographic characteristics, and test results in the log book was excluded.
Data collection and tools
We collected data from hepatitis B and C suspected clients' serology Laboratory registration logbooks using a structured checklist. Patient information, including age, sex, laboratory results, and year of diagnosis, was obtained from the serology laboratory registration logbooks.
Quality control
We used different methods to ensure that the collected data had the required quality. For instance, we used a structured data collection checklist and regular communication with the hospital staff working at the serology laboratory. HBsAg and anti HCV positive clients’ serum was rechecked using ELISA by Amhara Public Health Institute referral laboratory in Bahir Dar. Finally, we checked the collected data, cleaned it manually, and entered SPSS version 2 for analysis.
Laboratory methods
About 5 ml of venous blood was collected from each study participant. Then, the serum was separated by centrifugation at 5000 RPM for 15 min and tested for HBsAg and anti-HCV using a one-step HBsAg test strip (Nantong Diagnosis Technology Co., Ltd., China) and a one-step HCV test strip (Nantong Diagnosis Technology Co., Ltd., China), respectively by following the manufacturer instructions. The sensitivity and specificity of rapid test kits of HBsAg and one-step HCV test strips were 99.1% and 99.6%, respectively.
Data processing and analysis
All participants’ information and laboratory data were entered and then analyzed using SPSS version 26 (IBM Corp., Armonk, NY). Descriptive analysis was used to describe and calculate the frequencies and percentages of variables. A chi-square test of proportions was used to identify a significant difference between variables, and a p-value < 0.05 was considered statistically significant.
Ethics approval and consent to participate
Ethical approval was obtained ethical clearance from the University of Gondar; School of Biomedical and Laboratory Sciences ethical review committee with reference number SBMLS/2934/2022. We conducted the study by following the Declaration of Helsinki. Before data collection, we explained the study objectives to the heads of the hospital director and the serology laboratory personnel. Due to the nature of this retrospective study and the preserved anonymity of patients, a waiver of informed consent was obtained. The waivers of informed consent were the University of Gondar; School of Biomedical and Laboratory Sciences and Guhala primary hospital. To ensure the confidentiality of information from the participant’s records, we didn’t record any personal identifiers on the data collection sheet, and secured data from participant records were not available to anyone except for the investigators15.
Results
Socio-demographic characteristics of study participants
In the past four years (2017–2021), a total of 883 study participants were suspected of HBV, and all of them were given blood samples at the Guhala Primary Hospital serology laboratory. Most of them, 473 (53.6%) were females. The age of patients ranges from one to eighty-five years and the mean age of the patients was 30.7 years (± 14.6 SD). Most of the samples were tested in 2019 (41.7%), followed by 2021 (28.7%) and 2018 (20.5%). The majority of the samples came from patients between the ages of 21 and 30 (38.8%), followed by those the age between 1 and 20 (24.5%), and those the ages of over 40 (19.9%). On the other hand in the past 5 years (2017–2021), a total of 366 blood samples were collected and tested from HCV-suspected study participants at the Guhala Primary Hospital serology laboratory. Most of them, 221 (60.4%) were males (Table 1).
Sero-prevalence of HBV and HCV infections
In this study, the overall prevalence of HBsAg and anti-HCV were 124/883 (14%) and 73/366 (19.9%), respectively. Among the study participants, the positivity rate of HBsAg was 17.1% (70/410) among males and 54/473 (11.4%) females. Additionally, Out of the total HCV screening samples, 53/366 (14.4%) males, and 20/366 (5.5%) females were positive for hepatitis C, respectively. The prevalence of Hepatitis B virus was higher among individuals aged between 31 to 40 years old 33/148 (22.3%) followed by individuals aged > 40 years old 29/176(3.3%). On the other hand, the prevalence of hepatitis C virus was high among the age group > 40 years old 25/93(6.8%) followed by 31–40 years old 14/70 (3.8%). Of HBV and HCV mixed-infected 14 (3.8%) study participants, 3% were males and 0.8% were females. The majority of Coinfected study participants were 31–40 years old 7 (1.9%). Moreover, the highest prevalence of HBV was seen by the year of 2019, and also the highest prevalence of HCV was seen by the year of 2018, While, the lowest prevalence of HBV and HCV was seen in the year of 2020 (Table 2, Fig. 1).
Factors associated with hepatitis B virus infections
Multivariate logistic regression was performed to account for possible confounding variables and all variables with a P-value < 0.2 in the bivariate analysis were included in the multivariate logistic regression analysis. Accordingly, the adjusted odds ratio was calculated between different age groups and sex and HBV infection. According to bivariate analysis being female and age showed an association with hepatitis B virus infection and transported to multivariate analysis. Based on the multivariable logistic regression model, females were 1.53 times more likely (AOR 1.53; 95% CI 1.03, 2.27) to be infected with HBV than males. furthermore, participants who were in the age group of 31–40 years were two times more likely (AOR 2.85; 95% CI 1.56, 5.17) to be infected with HBV than those who were in the age group 21–30 years (Table 3).
Factors associated with HCV infection
In the multivariable logistic regression analysis, females were around two times more likely (AOR 1.97; 95% CI 1.10, 3.53, p = 0.02) to be infected with HCV than males. Additionally, study participants who were in the age group of 21–30 years were 2.7 times more likely (AOR 2.71; 95% CI 1.15, 6.40, p = 0.02) and age group of greater than 40 years were three times more likely (AOR 3.13; 95% CI 1.31, 7.44, p = 0.01) to be infected with HCV than those who were in the age group less than 20 years (Table 4).
Discussion
HBV and HCV are two common sexually transmitted infections (STIs) that represent a significant public health concern in sub-Saharan Africa and are common in developing countries16. The primary indicators of the endemicity of HBV and HCV infection in the general population in a given geographic area are hepatitis B surface antigen (HBsAg) and anti-HCV17. According to WHO criteria18, The prevalence of HBV infection can be graded high when the prevalence is > 8%, intermediate when the prevalence is between 2 and 8%, and low when the prevalence is < 2%19. Hepatitis C virus infection can be also graded high, moderate, or low when the prevalence is > 3.5, 1.5–3.5%, and ˂ 0.1.5%20.
In the present study, we found that 14% and 19.9% of the overall Sero-prevalence of HBsAg and Anti-HCV among patients screened for HBV and HCV infection in Guhala Primary Hospital, respectively. Based on the WHO classification, the prevalence of HBV infection in this study was classified as "High". This figure is still high if we compute the general population of Ethiopia as these days it is close to 117 million. In addition, it is assumed that the rate might be increased more if this study is done in different geographical areas. Therefore, HBV and HCV infection was a particular problem that might be due to the possibility all the populations are at risk for HBV and HCV infection21.
In our study, the prevalence rate of HBsAg 14% was comparable with a study conducted in Gondar among patients attending serology laboratory of Gondar University Hospital 14.4%3. However, this finding is higher than another study conducted in Gondar among blood donors 4.7%22, a study done in Gondar among street dwellers 10.9%23 and medical waste handlers 6%24, Bahirdar among military personnel 4.2%25 and among patients Attending at Addis Alem Primary Hospital 3.9%26, Mekele among blood donors 6.2%27, Addis Ababa among blood donors 3.0%28, in Addis Ababa, Ethiopia among medical waste handlers 6.3%29, in Addis Ababa among general population 7%30, southern Ethiopia among VCT clients 5.7%31, Jigjiga among blood donors 10.9%32, in Eretria on blood donors 2.6%33, and 2.0%34, and Northern Nigeria among blood donors 10.9%35, and the study reported Japan 0.8%36. Furthermore, our study was lower than the study conducted among donors at Bahir Dar, Ethiopia 25%37, in southeast Ethiopia among patients with chronic hepatitis 22.3%38, in Addis Ababa among Chronic liver disease patients 57.5%39, and in Nigeria among blood donors 18.6%40. These variations may be attributed to variances in sample size, geographic variance, detection technique, cultural practices, and behavioral divergences for the risk factors. Additionally, the degree of HBV endemicity is frequently correlated with the major mode of transmission. Moreover, the variation may also result from various research designs and techniques for the HBV infection assay.
In the current study, the overall prevalence of anti-HCV was 19.9%. This study was higher than the study conducted Gondar among patients attending serology laboratory of Gondar University Hospital 12.4%3, southeast Ethiopia among patients with chronic hepatitis 3.6%25, in Nigeria among Patients with Suspected Liver Diseases 4.4%41, in southeastern Nigeria among the outpatients attending the general hospital 4.39%42, and 12.9% in Nigeria among urban and rural communities 12.9%43, and in Pakistan among the patients reporting in surgical OPD 10.8%44, in contrast this study lower than study conducted in Addis Ababa among CLD patients 57.5%39, and in Pakistan among patients seeking hospital care 23.5%45.
In this study, the highest prevalence was recorded among the age group between 31 and 40 years 33 (22.3%) which was higher than the seroprevalence of all other age groups 0–20 years 20 (9.3%), 21–30 years 42 (12.24%), and > 40 years 29 (3.3%). This study is in agreement with studies conducted in Ghana on blood donors, revealing that the highest seroprevalence was among the 30–39 years age group 8.9%46. However, our study is not in agreement where the highest prevalence was recorded among the age group between 21 and 30 years 48 (2.4%)26.
In the present study, Among the study participants, the positivity rate of HBsAg was higher in males (17.1%) than females. Our study is in disagreement with studies done in Bahir Dar, Ethiopia where the positivity rate of HBsAg was higher in females (3.0%) compared to males 17 (0.8%)26 And a study done in Ghana where the positivity rate of HBsAg was higher in females (14.3%) compared to males 17 (6.7%)46. This vibration may be brought on by cultural activities like tattooing, bloodletting, and circumcisions that put a person at risk for HBV infection, as well as vaccination status47. Similarly, the positivity rate of HCV was higher in males (14.4%) compared to females. However, This finding is inconsistent with a study conducted in Gondar where the positivity rate of HCV was higher in males (7.6%) compared to females (4.13%)3, and in Pakistan where the positivity rate of HCV was higher in males (2.5%) compared to females (0.9%)45. This inconsistency might be due to variations in the study population,-screening methods, and study design.
In the current study, the prevalence of HBV-HCV co-infection was 3.8%. This finding is consistent with studies conducted in Gondar 2%3 and in Burkina Faso 2.2%48. However, this finding is inconsistent with the study conducted in Nigeria 8.3%49. We attempted to shed light on the hepatitis virus prevalence in our study because it hasn't been well investigated in this area.
Limitations of this study
Due to the study's reliance on secondary data, its limitations included incomplete data and an inadequate document-keeping system. Another drawback is that, because of budgetary constraints, laboratory testing has been restricted to detecting HBsAg and anti-HCV alone. ELISA and the Nucleic Acid Amplification Technique (NAAT) as a screening method were not done.h
Conclusion and recommendation
In our study, a high prevalence of HBV and HCV infection was found in clinically suspected patients. This study is female and the age group between 31 to 40 years more affected by HBV and HCV. This figure raises major issues regarding public health because hospital attendant clients are among the most vulnerable populations. Thus, it would be essential to establish protocols for routinely screening all hospital attendant clients for HBV and HCV infection.
Data availability
All data generated or analyzed during this study were included in this article.
Abbreviations
- Anti HC AB:
-
Anti hepatitis C virus antibody
- CI:
-
Confidence interval
- CLD:
-
Chronic liver disease
- HBsAg:
-
Hepatitis B surface antigen
- HBV:
-
Hepatitis B virus
- HCV:
-
Hepatitis C virus
- HBeAg:
-
Hepatites envelop antigen
- HBcAg:
-
Hepatites B core antigen
- SD:
-
Standard deviation
- SPSS:
-
Statistical package for social sciences
- WHO:
-
World health organization
References
Asemahagn, M. A. Epidemiology of hepatitis B and C virus infections among patients who booked for surgical procedures at Felegehiwot referral hospital, Northwest Ethiopia. PLoS ONE 15(6), e0234822 (2020).
Eke, A. C., Eke, U. A., Okafor, C. I., Ezebialu, I. U. & Ogbuagu, C. Prevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. Virol. J. 8(1), 1–8 (2011).
Tesfa, H. et al. Seroprevalence of hepatitis B and C virus infection among patients attending serology laboratory of Gondar University Hospital. BMC. Res. Notes 6(1), 1–4 (2013).
Schillie, S. et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 67(1), 1 (2018).
Goldstein, S. T. et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34(6), 1329–1339 (2005).
Organization, W. H. Global policy report on the prevention and control of viral hepatitis in WHO Member States. (2013).
Abeje, G. & Azage, M. Hepatitis B vaccine knowledge and vaccination status among health care workers of Bahir Dar City Administration, Northwest Ethiopia: A cross sectional study. BMC Infect. Dis. 15(1), 1–6 (2015).
Konstantinou, D. & Deutsch, M. The spectrum of HBV/HCV coinfection: Epidemiology, clinical characteristics, viralinteractions and management. Ann. Gastroenterol. Q. Publ. Hellenic Soc. Gastroenterol. 28(2), 221 (2015).
Ko, C.-C. et al. Dual hepatitis B and C-associated hepatocellular carcinoma: Clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade. Int. J. Clin. Oncol. 27(4), 739–748 (2022).
Brotman, B. et al. Interference between non-A, non-B and hepatitis B virus infection in chimpanzees. J. Med. Virol. 11(3), 191–205 (1983).
Bradley, D. W. et al. Non-A, non-B hepatitis in chimpanzees: Interference with acute hepatitis A virus and chronic hepatitis B virus infections. J. Med. Virol. 11(3), 207–213 (1983).
Chakravarti, A., Verma, V., Jain, M. & Kar, P. Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease: A study from tertiary care hospital. Trop. Gastroenterol. 26(4), 183–187 (2005).
Organization, W. H. Hepatitis B vaccines. Wkly. Epidemiol. Rec. Relevé épidémiologique hebdomadaire. 79(28), 255–263 (2004).
Conners, E. E. et al. Screening and testing for hepatitis B virus infection: CDC recommendations—United States, 2023. MMWR Recomm. Rep. 72(1), 1 (2023).
Abate, E. et al. Asymptomatic helminth infection in active tuberculosis is associated with increased regulatory and Th-2 responses and a lower sputum smear positivity. PLoS Negl. Trop. Dis. 9(8), e0003994 (2015).
Olokoba, A. et al. Hepatitis B virus infection amongst pregnant women in north-eastern-a call for action. Niger. J. Clin. Pract. 14(1), 10 (2011).
Shepard, C. W., Simard, E. P., Finelli, L., Fiore, A. E. & Bell, B. P. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol. Rev. 28(1), 112–125 (2006).
Hou, J., Liu, Z. & Gu, F. Epidemiology and prevention of hepatitis B virus infection. Int. J. Med. Sci. 2(1), 50 (2005).
Lawan, S., Gimba, S., Elyuguda, A., Sabo, H. & Dadile, H. Hepatitis B virus infection among prison inmates in Borno State: Determination of prevalence of surface antigen (HBsAg) and possible risk factors of disease. J. Hepat. Res. 6, 1041 (2021).
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 57(4), 1333–1342 (2013).
Schillie, S., Wester, C., Osborne, M., Wesolowski, L. & Ryerson, A. B. CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recomm. Rep. 69(2), 1 (2020).
Tessema, B. et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: Declining trends over a period of five years. BMC Infect. Dis. 10, 1–7 (2010).
Moges, F., Kebede, Y., Kassu, A., Mulu, A., Tirunch, M., Degu, G. et al. Seroprevalence of HIV, hepatitis B infections and syphilis among street dwellers in Gondar city, Northwest Ethiopia. Ethiop. J. Health Dev. 20(3) (2006).
Anagaw, B. et al. Seroprevalence of hepatitis B and C viruses among medical waste handlers at Gondar town Health institutions, Northwest Ethiopia. BMC Res. Notes. 5(1), 1–10 (2012).
Birku, T., Gelaw, B., Moges, F. & Assefa, A. Prevalence of hepatitis B and C viruses infection among military personnel at Bahir Dar Armed Forces General Hospital, Ethiopia. BMC Res. Notes. 8(1), 1–6 (2015).
Geta, M., Yizengaw, E., Getaneh, Z. & Getahun, T. Seroprevalence of hepatitis B virus infection among patients attending at Addis Alem Primary Hospital, Bahir Dar, Northwest Ethiopia. Int. J. Gen. Med. 14, 405–411 (2021).
Gelaw, B. & Mengitsu, Y. The prevalence of HBV, HCV and malaria parasites among blood donor in Amhara and Tigray regional states. Ethiop. J. Health Dev. 22(1), 3–7 (2008).
Tegegne, D., Desta, K., Tegbaru, B. & Tilahun, T. Seroprevalence and transmission of Hepatitis B virus among delivering women and their new born in selected health facilities, Addis Ababa, Ethiopia: A cross sectional study. BMC Res. Notes. 7(1), 1–7 (2014).
Shiferaw, Y., Abebe, T. & Mihret, A. Hepatitis B virus infection among medical waste handlers in Addis Ababa, Ethiopia. BMC Res. Notes. 4, 1–7 (2011).
Abebe, A. et al. Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: Transmission patterns and vaccine control. Epidemiol. Infect. 131(1), 757–770 (2003).
Negero, A., Sisay, Z. & Medhin, G. Prevalence of Hepatitis B surface antigen (HBsAg) among visitors of Shashemene General Hospital voluntary counseling and testing center. BMC Res. Notes. 4(1), 1–5 (2011).
Mohammed, Y. & Bekele, A. Seroprevalence of transfusion transmitted infection among blood donors at Jijiga blood bank, Eastern Ethiopia: Retrospective 4 years study. BMC Res. Notes. 9(1), 1–6 (2016).
Fessehaye, N., Naik, D., Fessehaye, T. Transfusion transmitted infections—A retrospective analysis from the National Blood Transfusion Service in Eritrea. Pan Afr. Med. J. 9(1) (2011).
Siraj, N. et al. Seroprevalence of transfusion-transmissible infections among blood donors at National Blood Transfusion Service, Eritrea: A seven-year retrospective study. BMC Infect. Dis. 18(1), 1–9 (2018).
Nwankwo, E., Momodu, I., Umar, I., Musa, B. & Adeleke, S. Seroprevalence of major blood-borne infections among blood donors in Kano, Nigeria. Turk. J. Med. Sci. 42(2), 337–341 (2012).
Merican, I. et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 15(12), 1356–1361 (2000).
Dessie, A., Abera, B. & Wale, F. Seroprevalence of major blood–borne infections among blood donars at Felege Hiwot referral hospital, Northwest Ethiopia. Ethiop. J. Health Dev. 21(1), 68–69 (2007).
Taye, S., Abdulkerim, A. & Hussen, M. Prevalence of hepatitis B and C virus infections among patients with chronic hepatitis at Bereka Medical Center, Southeast Ethiopia: A retrospective study. BMC Res. Notes. 7(1), 1–4 (2014).
Abdelmenan, S., Banes, A., Berhane, Y., Abebe, M. & Wandall, J. Etiology of chronic liver disease in Ethiopia: A case control study with special reference to viral hepatitis and alcohol. EC Gastroenterol. Digest. Syst. 5(3), 120 (2018).
Buseri, F. I., Muhibi, M. A. & Jeremiah, Z. A. Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, south-west Nigeria. Blood Transfus. 7(4), 293 (2009).
Mohammed, A., Okwong, O. K., Jibrin, Y. B., Sabo, U. M. & Toyin, A. Serological screening of HBV and HCV among patients with suspected liver diseases seen at a Tertiary Hospital in Bauchi, Nigeria. Asian J. Res. Rep. Gastroenterol. 1(1), 6–12 (2018).
Donbraye, E., Japhet, M., Adesina, A. & Abayomi, O. Prevalence of asymptomatic hepatitis B virus surface antigenemia in children in llesha, Osun state, south-Western Nigeria. Afr. J. Micro Res. 8(23), 2329–2331 (2014).
Okonkwo, U. et al. Prevalence of hepatitis B, hepatitis C and human immunodeficiency viruses, and evaluation of risk factors for transmission: Report of a population screening in Nigeria. S. Afr. Med. J. 107(4), 346–351 (2017).
Ishtiaq, A. et al. Seroprevalence of hepatitis-B and C among the patients reporting in surgical OPD at Fauji Foundation Hospital. J. Med. Sci. 4, 514–517 (2007).
Khan, J. et al. Seropositivity and coinfection of hepatitis B and C among patients seeking hospital care in Islamabad, Pakistan. BioMed Res. Int. 2014, 1–4 (2014).
Walana, W. et al. Sero-prevalence of HIV, HBV and HCV among blood donors in the Kintampo Municipal Hospital, Ghana. Br. Microbiol. Res. J. 4(12), 1491–1499 (2014).
Sorrell, M. F. et al. National Institutes of Health consensus development conference statement: Management of hepatitis B. Ann. Intern. Med. 150(2), 104–110 (2009).
Zeba, M. Prevalence of HBV and HCV markers among patients attending the Saint Caınille Medical Centre in Ouagadougou* MTA Zeba," CAT Ouattara," SD. Karou,''C. Bisseye," D. Ouermi," FW Djigma,"" T. Sagna,"* V. Pietra," R. Moret," J. Nikiema and" J. Simpore" Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE. Pak. J. Biol. Sci. 15(10), 484–489 (2012).
Pennap, G. R., Yakubu, A., Oyige, O. & Forbi, J. Prevalence of hepatitis B and C virus infection among people of a local community in Keffi, Nigeria. Afr. J. Microbiol. Res. 4(4), 274–278 (2010).
Acknowledgements
We would like to thank the Guhala primary hospital staff, and its staff working at the serology laboratory.
Funding
The authors did not receive specific funding for this work.
Author information
Authors and Affiliations
Contributions
D.B.: conception and design of the work, data acquisition, analysis, and interpretation, drafting the manuscript, revising the manuscript; E.F., M.K., M.F., A.J., T.M., M.A., G.A., W.A. and A.A. conception and design of the work, data acquisition, and analysis; D.B., W.A., G.A., and A.A.: data interpretation, manuscript revision, and supervision. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Belete, D., Fekadie, E., Kassaw, M. et al. Seroprevalence of hepatitis B and hepatitis C virus among clinically suspected cases of viral hepatitis visiting Guhalla Primary Hospital, Northwest Ethiopia. Sci Rep 14, 21956 (2024). https://doi.org/10.1038/s41598-024-71363-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-024-71363-w
- Springer Nature Limited